Company: EUDAW
Filing Date: 2025-04-29
Form Type: 20-F
Source: 0001641172-25-006627
Chunk: 53

Company: EUDA Health Holdings Ltd
Filing Date: 2025-04-29
Form: 20-F
Item: Item 5
Chunk 53
---
3.

Net
cash used in investing activities was approximately $0.3 million for the year ended December 31, 2022, which was primarily attributable
to loan to third party of approximately $0.2 million and net cash used in investing activities from discontinued operations of approximately
$22,000.

Financing
Activities

Net
cash provided by financing activities was approximately $2.3 million for the year ended December 31, 2024 and was primarily
attributable to (i) approximately $1.5 million proceeds received from issuance of convertible notes, (ii) approximately $50,000
proceed received from issuance of ordinary shares through private placements, (iii) approximately $0.8 million proceeds received
from short-term loans from private lenders, (iv) approximately $0.4 million proceeds received from short-term loans from a related
party, and (v) approximately $0.3
million from discontinued operations entities, offset by (i) approximately $0.3 million repayment of convertible note, (ii)
approximately $0.3 million repayment to short-term loans from private lenders, (iii) approximately $0.1 million repayment to
other payables- related parties.

Net
cash provided by financing activities was approximately $2.7 million for the year ended December 31, 2023 and was primarily attributable
to (i) approximately $0.8 million issuance of ordinary shares through private placements, (ii) approximately $1.2 million proceeds from
short-term loans from related patties, (iii) approximately $0.5 million borrowings from other payables from related parties, and (iv)
approximately $0.5 million in borrowings from discontinued operations entities, offset by (i) net cash used in financing activities from
discontinued operations of approximately $0.4 million, and (ii) approximately $6,000 payments of finance lease liabilities.

  35  

Net
cash provided by financing activities was approximately $2.5 million for the year ended December 31, 2022 and was primarily attributable
to (i) approximately $0.3 million repayments from other receivable from related parties, (ii) $0.5 million issuance of ordinary shares,
(iii) approximately $0.6 million receipt of subscribed shares deposit, (iv) approximately $1.3 million proceeds from Reverse Recapitalization,
(v) net cash provided by financing activities from discontinued operations of approximately $1.5 million, (vi)